Myocardial infarction rapid test for qualitative detection of MYO, CK-MB and cTnI
A myocardial infarction can begin suddenly without warning. Typical symptoms include sudden pressure or squeezing pain in the chest that may radiate to the arms, jaw or back. Shortness of breath, weakness, nausea or unusual indigestion may also occur.
Call the local emergency number immediately if acute or persistent chest pain or shortness of breath occurs. Performing this test must never delay emergency assessment or treatment.
What does the myocardial infarction rapid test detect?
This CE-marked in vitro diagnostic test for professional use qualitatively detects myoglobin (MYO), creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) in whole blood, serum or plasma. It supports preliminary assessment of cardiac injury markers together with symptoms, ECG findings and other clinical information. The rapid test does not diagnose or rule out myocardial infarction on its own.
When do cardiac markers rise?
Myoglobin may rise approximately 2–4 hours after symptom onset and return to baseline within 24–36 hours. CK-MB may rise after approximately 3–8 hours and return to baseline within 48–72 hours. cTnI may rise after approximately 4–6 hours and remain elevated for 6–10 days. A negative result early after symptom onset does not exclude acute myocardial infarction.
Detection limits and result time
- Myoglobin: 50 ng/mL
- CK-MB: 5 ng/mL
- Cardiac troponin I: 0.5 ng/mL
- Result time: read at 10 minutes; do not interpret after 20 minutes
- Samples: whole blood, serum or plasma
- Intended use: professional use only
Package contents
- 10 individually foil-pouched test cassettes
- disposable droppers and desiccant sachets in the foil pouches
- one buffer bottle sufficient for 10 tests
- instructions for use in English and Finnish
Please note: lancets are not included and must be ordered separately for fingerstick whole-blood sampling.
How is the result interpreted?
Allow the cassette, buffer and specimen to reach room temperature before testing. Add the specimen and buffer exactly as described in the instructions for use. The control line C must always appear. A visible marker line may indicate that the concentration is at or above the stated detection limit. If the control line does not appear, the result is invalid and the test must be repeated.
Performance
The manufacturer reports relative sensitivity of 99.9% for MYO and CK-MB and 99.4% for cTnI against clinical comparator methods. Reported specificity is 97.2% for MYO, 99.4% for CK-MB and 99.0% for cTnI. These performance figures do not mean that the test alone confirms or excludes myocardial infarction.
Delivery and risk of freezing
The kit contains liquid buffer reagent. During winter delivery outside Finland, choose delivery to a pickup point to reduce the risk of freezing in transit. Freezing may impair test performance.
Storage and intended users
Store at 2–30 °C in the original sealed pouch. Do not freeze. The product is intended for healthcare professionals and has not been evaluated for home use.
The role of diet in cardiovascular health
Importer: Abcell Oy
Order the 10-test MYO/CK-MB/cTnI kit for professional use and add lancets to the same order when required.
